Chart Venture Partners
Innovative Biosensors, Inc. Expands Scientific Advisory Board
Press Release Source: Innovative Biosensors Inc. (IBI) 06/19/2007
Joe Hernandez
Rockville, MD, June 19, 2007 – Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the clinical and biodefense markets, today announced the expansion of its Scientific Advisory Board.
“We are pleased to announce the addition of Dr. James W. Snyder and Dr. Raymond Mackay to IBI’s Scientific Advisory Board," said Joe Hernandez, President and CEO. "These individuals are leaders in key technical areas and bring essential industry experience to the Board, which will be instrumental in our product development efforts”.
James W. Snyder, Ph.D. is a professor in the Department of Pathology and Laboratory Medicine and Chief of Microbiology at the University of Louisville Hospital and Associate Faculty at the Center for Deterrence of Biowarfare and Bioterrorism. Dr. Snyder earned his Ph.D. in Biology (Medical Microbiology) from the University of Dayton. He has also been a Member of the Laboratory Response Network Working Group for Preparation and Response to Bioterrorism since 2000. His specialties include medical mycology, bioterrorism, and molecular diagnostics of infectious diseases with research focus on product and instrument evaluation.
Raymond Mackay, Ph.D., was a research associate at SUNY, in the Nuclear Engineering Department at Brookhaven National Laboratory, received a doctoral degree from SUNY Stony Brook, served as a Captain in the U.S. Army, and joined Drexel University in Philadelphia, Pennsylvania as a Professor of Chemistry. He then became Director of the New York State-sponsored Center for Advanced Materials Processing at Clarkson University and became the Director, Research and Technology, at the Edgewood Chemical Biological Center of the U.S. Army in 2003. An author / co-author of over 140 technical publications, he completed a 13-year tenure as an Associate Editor of the Journal of the American Oil Chemists' Society in 1997. His list of awards and honors, include the Meritorious Civilian Service Medal, the Army's second highest civilian honor and the Maryland Chemist of the Year award from the American Chemical Society. Recently, Dr. Mackay received the Exceptional Civilian Service Award, which is the highest civilian award in the Department of the Army. He is currently working for the Army (ECBC) in the capacity of science advisor.
About Innovative Biosensors, Inc.
Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics. IBI’s technology has been tailored to rapidly and sensitively detect biological threats in building security, military, and civil defense applications. Additionally, the technology platform is being used to develop rapid tests for the detection of hospital-acquired infections. Additional information is available at www.innovativebiosensors.com.
This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors, Inc.’s mission to develop and commercialize instrument systems, Innovative Biosensors, Inc.’s ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Innovative Biosensors, Inc. cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensors, Inc.’s expectations that they will incur operating losses in the near future, the early stage of preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors, Inc.’s reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors, Inc.’s products, processes and technologies, Innovative Biosensors, Inc.’s ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.
Contact:
Joe Hernandez
President and CEO
Innovative Biosensors, Inc.
Phone: 301.517.0324
www.innovativebiosensors.com
info@innovativebiosensors.com
|